• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief


Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

Dear Colleagues,

World Diabetes Day is celebrated annually on No- vember 14 — the birthday of Frederic Banting. Each year World Diabetes Day carries a particular theme to bring the public’s attention to the various aspects of the disease. This year was celebrated in Poland under the slogan “Woman and man. Does diabetes have a gen- der?” paying particular attention to gender-related differences in the course of the disease.

Therefore, the current issue of “Clinical Diabeto- logy” includes papers addressing currently discussed problems concerning both women and men with diabetes. In this respect, it is worth noting the original article on the important but sometimes overlooked aspect of the everyday life of people with diabetes, which is sexual dysfunction. The authors assessed the satisfaction of the sexual life of patients with diabetes, emphasizing that it is an important component of the well-being of each patient, regardless of gender.

Another interesting article discussing gender-related problems is the original paper on nutritional choices in pregnant women, including those with gestational diabetes whose incidence is constantly increasing. The paper indicates that the type of diet appears to be a significant contributing factor.

However, regardless of gender, diabetes increases cardiovascular risk, and therefore antidiabetic drugs are not only required to be effective in lowering blood

glucose but also provide cardiovascular safety, i.e. they are expected to not increase the risk of cardiovascular events, or even to reduce it. Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that we have drugs that have protective effect on the cardiovascular system, of which empagliflozin and liraglutide additionally reduce cardiovascular morta- lity. However, practitioners are expecting with great interest the results of trials assessing other molecules including another SGLT2 inhibitor — dapagliflozine.

Therefore, the current issue includes an article about the effect of this molecule on the cardiovascular sys- tem. A large multicentre, randomized, double-blind, placebo-controlled phase IIIB trial with dapagliflozin, DECLARE-TIMI58 (Dapagliflozin Effect on Cardiovas- cuLAR Events), is under way. The study aims to assess cardiovascular risk and is scheduled to be completed in 2019. Its results will answer the question whether, in terms of cardiovascular risk, there is a class effect of SGLT2 inhibitors.

As usual, I invite you not only to read, but also to actively contribute to our journals, “Clinical Diabeto- logy” and “Diabetologia Praktyczna”, by submitting interesting papers and comments on the topics dis- cussed by other authors.


Prof. Janusz Gumprecht



Powiązane dokumenty

Jacek Górski, Director of the Museum of Archaeology in Krakow, Andrzej Grzymkowski of the Museum in Mława, Anna Kaszubowska of the Regional Museum in Bydgoszcz, Krystyna

„Rodzina w systemie wsparcia społecznego i pomocy osobom z problemem alkoholowym”, zorganizowana przez Pracownię Pedagogiki Specjalnej, w ramach realizowanego

Wyniki badania ACCORD Lipid wzmacniają pozycję terapii skojarzonej w podgrupie chorych z niskim stężeniem cholesterolu frakcji HDL i podwyż- szonym stężeniem triglicerydów,

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79 th Scientific Sessions of the American Diabetes

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

A panel of endocrinologists and physicians special- ising in the management of diabetes met to develop a consensus statement regarding the CV safety of the various

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to